Lv31
368 积分 2020-10-12 加入
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
2小时前
待确认
Phase 1 Trial of BCL-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Other Non-Hodgkin Lymphomas
11天前
已完结
Azacitidine–Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia
23天前
已完结
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
2个月前
已完结
Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study
3个月前
已完结
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia
5个月前
已完结
Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML
5个月前
已完结
Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies
5个月前
已完结
Targeting BCL-2 in Hematologic Malignancies
6个月前
已关闭
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
8个月前
已完结
皖公网安备34019202002308
